Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Foghorn Therapeutics's operating cash flow per share for the
three
months ended in Jun. 2026 was $-0.25.
Foghorn Therapeutics's operating cash flow per share for the trailing twelve months (TTM) ended in Jun. 2026 was $-1.27.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the OCF Growth Rate using Operating Cash Flow per Share data.
The historical rank and industry rank for Foghorn Therapeutics's Operating Cash Flow per Share or its related term are showing as below:
During the past 8 years, Foghorn Therapeutics's highest 3-Year average Operating Cash Flow per Share Growth Rate was 0.20% per year. The lowest was -10.60% per year. And the median was -5.40% per year.
FHTX's 3-Year OCF Growth Rate is not ranked *
in the Biotechnology industry.
Industry Median: 17 * Ranked among companies with meaningful 3-Year OCF Growth Rate only.
Foghorn Therapeutics Operating Cash Flow per Share Related Terms
Foghorn Therapeutics Operating Cash Flow per Share Historical Data
* Premium members only.
The historical data trend for Foghorn Therapeutics's Operating Cash Flow per Share can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Foghorn Therapeutics Operating Cash Flow per Share Chart
FHTX vs LYEL, ZNTL, PALI: Operating Cash Flow per Share Comparison
For the Biotechnology subindustry, Foghorn Therapeutics's Price-to-Operating-Cash-Flow, along with its competitors' market caps and Price-to-Operating-Cash-Flow data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Foghorn Therapeutics Price-to-Operating-Cash-Flow vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Foghorn Therapeutics's Price-to-Operating-Cash-Flow distribution charts can be found below:
* The bar in red indicates where Foghorn Therapeutics's Price-to-Operating-Cash-Flow falls into.
Operating Cash Flow per Share for the trailing twelve months (TTM) ended in Jun. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $-1.27
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
What does a Operating Cash Flow per Share of $-1.27 mean?
Foghorn Therapeutics (FHTX) has a Operating Cash Flow per Share of $-1.27 as of Jun. 2026. Operating cash flow per share equals the per-share amount of cash flow from operations. View historical data on Foghorn Therapeutics and its competitors. According to the industry distribution chart, Foghorn Therapeutics ranks #999999 out of 1133 companies in the Biotechnology industry.
Is Foghorn Therapeutics' Operating Cash Flow per Share too high?
Foghorn Therapeutics' current Operating Cash Flow per Share is $-1.27. Based on the distribution chart, Foghorn Therapeutics ranks #999999 out of 1133 companies in the Biotechnology industry, which is in the bottom quartile relative to peers. Overall, Foghorn Therapeutics has a GF Score™ of 70/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does Foghorn Therapeutics' Operating Cash Flow per Share compare to LYEL and ZNTL?
According to the Biotechnology industry distribution chart, Foghorn Therapeutics ranks #999999 out of 1133 companies for Operating Cash Flow per Share. This places Foghorn Therapeutics in the lower half of its industry. The industry median Operating Cash Flow per Share is 17.00. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Operating Cash Flow per Share for a Biotechnology company?
The median Operating Cash Flow per Share among Biotechnology companies is 17.00, based on 1,133 companies in the industry. Companies in the top quartile (top 25%) have a Operating Cash Flow per Share significantly above this median, while those in the bottom quartile fall well below. However, Operating Cash Flow per Share should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Operating Cash Flow per Share mean?
A high Operating Cash Flow per Share can signal that a stock is expensive relative to its fundamentals. Operating cash flow per share equals the per-share amount of cash flow from operations. View historical data on Foghorn Therapeutics and its competitors. For the Biotechnology industry, the median Operating Cash Flow per Share is 17.00 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Foghorn Therapeutics's current Operating Cash Flow per Share is $-1.27. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Foghorn Therapeutics stock overvalued right now?
Based on GuruFocus' analysis, Foghorn Therapeutics (FHTX) is currently considered Fairly Valued. The stock's GF Value™ is $5.26, compared to a current price of $4.80 — trading 8.7% below its estimated fair value. The current Operating Cash Flow per Share is $-1.27. Foghorn Therapeutics' overall GF Score™ is 70/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Operating Cash Flow per Share calculated?
Operating Cash Flow per Share is calculated from a company's financial statements. For Foghorn Therapeutics (FHTX), the current Operating Cash Flow per Share is $-1.27 as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Foghorn Therapeutics (FHTX) Overvalued in 2026?
Based on GuruFocus' analysis, Foghorn Therapeutics stock appears to be undervalued.
The current stock price of $4.80 is trading 8.7% below its estimated GF Value™ of $5.26.
GuruFocus considers Foghorn Therapeutics to be Fairly Valued.
Key valuation signals for FHTX:
Operating Cash Flow per Share: $-1.27
GF Value™: $5.26 vs. price of $4.80 (8.7% below fair value)
No single metric tells the full story. See the FHTX stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Foghorn Therapeutics Inc is a clinical stage, precision therapeutics biotechnology company focused on pioneering a new class of medicines that treat serious diseases by correcting abnormal gene expression through selectively targeting the chromatin regulatory system. Its proprietary platform is designed to provide an integrated, mechanistic understanding of interactions within the chromatin regulatory system, supporting the identification and validation of potential therapeutic targets. The company's flagship program is FHD-909.
70GF Score
Get the complete analysis for FHTX
Operating Cash Flow per Share is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
FHTX has been successfully added to your 
